CLU expression and the extracellular signal-regulated kinase (ERK) / matrix metalloproteinase-9 (MMP) signalling pathway in human breast cancer cells. METHODS: A pcDNA3.1-based RNA interference approach was used to knockdown the CLU gene in MDA-231 cells (MDA-231-CLUi); control MDA-231 cells were transfected with an empty vector (MDA-231-Vec). Reverse transcriptionpolymerase chain reaction was used to assess CLU and MMP-9 mRNA levels, and Western blotting was used to analyse CLU, MMP-9 and ERK protein levels. Metastatic potential was evaluated using in vitro and in vivo models of invasion and metastasis. RESULTS: Compared with MDA-231-Vec cells, the MDA-231-CLUi cells demonstrated reduced migration and invasion in vitro and decreased metastatic potential in vivo. Reintroduction and reexpression of the CLU gene into the MDA-231-CLUi cells restored the invasive phenotype. MMP-9 mRNA and protein levels were reduced in MDA-231-CLUi cells, and there was a correlation between activated ERK and CLU and MMP-9 protein levels. CONCLUSION: CLU may regulate the aggressive behaviour of human breast cancer cells through modulation of ERK signalling and MMP9 expression. KEY WORDS: CLUSTERIN; MATRIX METALLOPROTEINASE-9 (MMP-9); EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK); BREAST CANCER; METASTASIS J Li, L Jia, P Zhao et al. Clusterin silencing in human breast cancer cells •
Introduction
Clusterin (CLU), also known as testosteronerepressed prostate message-2 or sulphated glycoprotein-2, was first isolated from ram rete testis fluid and has important roles in various pathophysiological processes, including tissue remodelling, adhesion, apoptosis, cell proliferation, senescence, membrane recycling, lipid transportation, complement inhibition and sperm maturation. 1 A growing body of evidence has suggested a prominent role for the upregulation of CLU in tumour pathogenesis and progression. Increased expression of the CLU gene has been reported in several malignancies, including hepatocellular, 2 pancreatic, 3 colorectal, 4 ovarian, 5 prostate, 6 bladder 7 and kidney 8 cancers. Several studies have shown a correlation between overexpression of the CLU gene and tumour metastasis in melanoma, 9 gastric cancer 10 and renal cell carcinoma. 7, 11 It has also been shown that CLU protein levels are higher in breast cancer tissue compared with tissues without lymph node metastasis and that expression of the CLU gene may serve as a new prognostic marker for breast cancers. 12, 13 Furthermore, it was reported that introduction of the CLU gene into MCF-7 breast cancer cells resulted in enhanced formation of metastatic nodules in vivo, 14 but it is unknown whether silencing the CLU gene could inhibit tumour metastasis.
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases. MMP-9 is closely associated with tumour invasion and metastasis in human breast cancer 15 but the mechanisms of MMP9 gene activation in human cancer cells are not well defined. The production of MMP-9 can be induced by CLU, which also serves as a regulator of extracellular signal-regulated kinase 1/2 (ERK1/2)-induced expression of the MMP9 gene. 16 -19 The present study examined the effects of silencing CLU expression on cell migration and invasion in experimental in vitro and in vivo models of metastasis in a human breast cancer cell line (MDA-231), and investigated the relationship between CLU expression and the ERK/MMP signalling pathway with respect to the prometastatic activity of CLU in human breast cancer cells.
Materials and methods TUMOUR CELL LINE
The human breast cancer cell line, MDA-231, was purchased from the American Type Culture Collection (Manassas, VA, USA). The cells were maintained in complete medium comprising McCoy's 5a medium (Gibco ® BRL, Life Technologies, Gaithersburg, MD, USA) supplemented with 10% heatinactivated fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml streptomycin, in a humidified atmosphere of 5% carbon dioxide at 37°C.
PLASMID SYNTHESIS
To silence CLU gene expression, the plasmid pcDNA3.1-clusterin-i (pcDNA3.1-CLUi) was generated. To do this, synthetic oligonucleotide primers CLUi-forward (5′-GATCCCCCCAGAGCTCGCCCTTCTACTTCA AGAGAGTAGAAGGGCGAGCTCTGGTTTTT GGAAA-3′) and CLUi-reverse (5′-AGCT TTTCCAAAAACCAGAGCTCGCCCTTCTACT CTCTTGAAGTAGAAGGGCGAGCTCTGGGG G-3′) were annealed and ligated into the pcDNA3.1(+) plasmid (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. Briefly, the pcDNA3.1(+) plasmid was transformed into the Escherichia coli DH5α strain by the calcium chloride method 20 and purified according to the manufacturer's protocols. The purified plasmid and oligonucleotide primers were digested with the HindIII and BamHI restriction enzymes at 37°C for 1 h, and the digested fragments were detected by 1.2% agarose gel electrophoresis and purified using an agarose gel DNA purification kit (Takara Biotechnology [Dalian] Co. Ltd, Dalian, China). A 20-µl ligation mix containing the oligonucleotide primers (10 nM in 7 µl) and pcDNA3.1(+) (0.4 µg in 1 µl), 1 µl of 10× ligation buffer, 1 µl T4 DNA ligase and 10 µl double-distilled water was J Li, L Jia, P Zhao et al. Clusterin silencing in human breast cancer cells incubated overnight at 16°C. The reconstructed plasmid was purified by cleaving with one (BamHI) and then two (HindIII and BamHI) restriction enzymes, and purified by 1.2% agarose gel electrophoresis. The purified plasmid was sequenced by Shanghai Jikang Biology Co. Ltd (Shanghai, China). The resulting plasmid contained short hairpin (sh)RNAs targeting 5′-CCAG AGCTCGCCCTTCTAC-3′, which corresponds to nucleotide positions 591 -609 of the CLU gene coding sequence (NM_001831; National Center for Biotechnology Information, Bethesda, MD, USA). It has been shown previously that efficient CLU silencing can be achieved by targeting this sequence. 21 For the reintroduction and re-expression of the CLU gene, a full-length human CLU cDNA was generated and cloned into the vector pIRES-CLU, as described previously. 22 Efficiency of the procedure was demonstrated by the detection of CLU protein on Western blotting.
PREPARATION OF CLU-SILENCED STABLE MDA-231 CLONES
To generate CLU-silenced (MDA-231-CLUi) and control vector (MDA-231-Vec) stable clones, MDA-231 cells were transfected with the pcDNA3.1-CLUi or empty pcDNA3.1 plasmid using Lipofectamine™ 2000 (Invitrogen), according to the manufacturer's instructions. Briefly, 1 day before transfection, cells (at 50 -80% confluency)
were trypsinized and resuspended in Dulbecco's modified Eagle's medium (DMEM; Gibco ® BRL, Life Technologies) without antibiotics and plated into a 24-well plate (2.0 × 10 4 cells per 0.6 ml per well). On the day of transfection the cells were resuspended in McCoy's 5a medium. Then MDA-231-CLUi or MDA-231-Vec plasmid (0.5 µg in 30 µl) and 90 µl Lipofectamine™ 2000 were added and the cells were incubated for 48 h at 37°C. The cells were then harvested for Western blot analysis to detect the degree of knockdown of exogenous CLU protein.
Stable transfectants were selected from transiently transfected clones by incubating at 37°C for 3 weeks in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin, and 600 µg/ml G418 (Geneticin™; Gibco ® BRL, Life Technologies). Stable transfectants were then routinely maintained in selection medium containing 200 µg/ml G418-sulphate to avoid overgrowth of nontransfected cells.
For the generation of transiently transfected clones in which the CLU gene had been reintroduced, stable MDA-231-CLUi cells (2 × 10 4 cells/ml) were transfected with 100 nM pIRES-CLU cDNA, using Lipofectamine™ 2000 for 4 h at 37°C, as described previously. 22 Cells were washed with 10 mM phosphate buffered saline (PBS), pH 7.4, and further incubated with complete medium for 48 h. Transiently transfected clones containing the pIRES-CLU cDNA plasmid were then analysed for CLU mRNA levels and protein using reverse transcription-polymerase chain reaction (RT-PCR) assay and Western blot, respectively, as described below.
CELL CULTURE CONDITIONS
To study the effect of CLU on ERKdependant MMP9 expression and metastasis in MDA-231 cells, stable transfectants (MDA-231-Vec and MDA-231-CLUi; 2 × 10 4 cells) in DMEM/10% FBS were treated with the mitogen-activated protein kinase (MEK) inhibitor PD98059 (50 µM) for 6 h at 37°C. Then, the treated cells had the CLU gene reintroduced using the pIRES-CLU cDNA plasmid, as described above.
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RT-PCR ANALYSIS OF CLU AND MMP-9 MRNA LEVELS
Cells (1 × 10 6 cells for each experimental condition) were harvested for total RNA isolation using TRIzol ® reagent (Invitrogen) according to the manufacturer's instructions. The RNA concentration was determined spectrophotometrically and the quality of RNA was assessed on a 1.2% denaturing agarose gel with MOPS buffer (40 mM MOPS pH 7.0, 10 mM sodium acetate, 1 mM ethylenediaminetetra-acetic acid).
The RT-PCR assay was performed with the Titanium ® One-Step RT-PCR kit (Clontech Laboratories, Mountain View, CA, USA), according to the manufacturer's instructions. Primer sequences were: CLU, 5′-AAGGA AATTCAAAATGCTGTCAA-3′ (sense) and 5′-ACAGACAAGATCTCCCGGCACTT-3′ (antisense); MMP9, 5′-CCTTCTACGGCCACTACT-3′ (sense) and 5′-GCACTGCAGGATGTCATA-3′ (antisense); tissue inhibitor of metalloproteinase-1 (TIMP1), 5′-GCGAACTGGAC ACACACACAGTTAT (sense) and 5′-CCCC AGTGTGAGTTCTAATGTGTCC (antisense); and glyceraldehyde 3-phosphate dehydrogenase, (GAPDH) 5′-TGCTTTTAACTC TGGTAAAGT-3′ (sense) and 5′-ATATTTGG CAGGTTTTTCTAGA-3′ (antisense). The PCR stage was performed under the following conditions: 50°C (55°C for CLU) for 60 min, 94°C for 5 min, immediately followed by 20 cycles (28 cycles for MMP9; 40 cycles for GAPDH) of 94°C for 30 s, 55°C for 30 s and 68°C for 1 min, followed by a final extension at 72°C for 2 min (10 min for TIMP1). The PCR products were analysed on a 1.5% agarose gel stained with ethidium bromide. The density of each band was normalized against that of GAPDH using the ImageMaster VDS-CL system (GE Healthcare Life Sciences, Little Chalfont, UK), and the mean ± SD intensity relative to that of GAPDH was calculated.
WESTERN BLOTTING ANALYSIS OF CLU, MMP-9 AND ERK PROTEIN
Cells (1 × 10 6 cells for each experimental condition) were washed twice with ice-cold 10 mM PBS, pH 7.4, then harvested using lysis buffer (20 mmol/l Tris-HCl, pH 7.6, 100 mmol/l saline, 20 mmol/l potassium chloride, 1.5 mmol/l magnesium chloride and 0.5% Nonidet P-40) containing phosphatase inhibitors (10 mmol/l sodium fluoride, 1 mmol/l trisodium vanadate and 50 mmol/l βglycerophosphate) and protease inhibitors (20 µg/ml leupeptin, 10 µg/ml pepstatin A and 4 µg/ml aprotinin). The protein concentration of each cell extract was measured using a bovine serum albumin protein assay kit (Bio-Rad, Hercules, CA, USA). Then, 20 µg of each cell lysate was separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and transferred onto a Hybond™-P polyvinylidene difluoride membrane (GE Healthcare Life Sciences). The membranes were blocked for 60 min at room temperature with 5% nonfat dry milk in 20 mM Trisbuffered saline, pH 7.6, containing 0.05% Tween-20 (TBST) and then incubated with the following specific FLAG ® -coupled primary antibodies overnight at 4°C: antihuman CLU (M-18, 1 : 100 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA); antihuman ERK (1 : 200 dilution; Cell Signaling Technology, Danvers, MA, USA); antihuman phosphorylated ERK (p-ERK, 1 : 200 dilution; Cell Signaling Technology); antihuman MMP-9 (1 : 250 dilution; Santa Cruz Biotechnology); and antihuman α- 
WOUND HEALING ASSAY
For the wound healing assay, the bottoms of six-well plates were marked as a reference point for wound healing under different conditions. The dishes were precoated with 3 ml of 10 µg/ml fibronectin (Shrgbio.com, Shanghai, China) overnight at 4°C. Any unbound fibronectin was removed by aspiration and the dishes were blocked with 3 ml of 2 mg/ml bovine serum albumin for 1 h at 37°C. Then, MDA-231-CLUi cells, MDA-231-Vec cells and native MDA-231 cells were seeded at 1 × 10 6 cells/well in DMEM / 10% FBS (without antibiotics) and cultured for approximately 24 h to near confluence.
A scratch wound, consisting of a cell-free line of approximately 20 cell diameters in width, was made perpendicular to the markings on the bottom of the dish using the tip of a P200 micropipette, and the medium was changed to remove detached cells. Phase contrast micrographs were taken immediately after the wound was made and 24 h later, and the number of cells migrating into the wound area was counted. Cells from three representative fields were counted.
IN VITRO CELL INVASION ASSAY
The in vitro invasion assay was performed using a 24-well transwell insert with polycarbonate filters (8-µm pore size; Becton, Dickinson and Co., Franklin Lakes, NJ, USA) according to the manufacturer's instructions.
Briefly, 60 µl of diluted extracellular matrix (ECM) gel solution (Matrigel™; Corning Costar, Cambridge, MA, USA) was put into the upper chambers of the transwell inserts. The inserts were incubated at 37°C for 4 h for gelling and then pretreated with serum-free DMEM at 37°C for 1 h before seeding cells at a density of 1 × 10 5 MDA-231-CLUi cells/well in 100 µl DMEM / 10% FBS (without antibiotics). The lower chambers of the transwells were filled with 500 µl DMEM / 10% FBS. The transwells were then incubated at 37°C with 5% carbon dioxide for 24 h, fixed with methanol and stained with haematoxylin for 10 min followed briefly by eosin. Cells in the upper chamber were removed by cotton swab and the cells that had invaded through the Matrigel™ and were located on the underside of the filter were counted using an optical microscope, choosing five randomly selected highpowered fields from a total of 16 fields/filter.
IN VIVO EXPERIMENTAL METASTASIS ASSAY
Female C57BL/6 mice (4 -6 weeks old, 14 -16 g in weight) were obtained from QingDao University. All animals were maintained in a sterile environment and cared for according to the animal laboratory regulations of the Ministry of Science and Technology, China. Autoclaved cages containing food and water were changed once a week. Mouse body weight was measured every 3 -4 days. The study protocol was reviewed and approved by the Ethics Committee of the Medical College of QingDao University.
The MDA-231-CLUi cells (1 × 10 6 cells in 50 µl) were injected into the tail veins of mice (n = 10) that were sacrificed 4 weeks later. Lung tissue was then harvested and fixed in Bouin's solution and surface nodules were counted under a dissecting microscope. For haematoxylin and eosin staining, lung tissue J Li, L Jia, P Zhao et al.
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was preserved overnight at room temperature in 10% neutral-buffered formalin equal to 20 times the tissue volume and then processed by standard paraffin embedding and sectioning. Then, 5-µm sections were deparaffinized and rehydrated in a graded ethanol series (100 -75%) and stained using Gill's haematoxylin and eosin followed by dehydration through a graded ethanol series (75 -100%). The number of microscopic pulmonary nodules was determined by counting five low-powered fields (×10 magnification) from each slide and calculating the mean number of nodules per field.
STATISTICAL ANALYSES
All statistical analyses were performed using SPSS ® statistical software, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Data are presented as mean ± SD of three independent experiments. Data were tested for statistical significance using the Student's t-test. A P-value < 0.05 was considered to be statistically significant.
Results
The Fig. 1C ) and significantly decreased invasion in the cell invasion assay (P < 0.001; Fig. 1D ).
There was a significant reduction in MMP-9 protein (P < 0.05; Fig. 2A ) and mRNA (P < 0.01; Fig. 2B ) in MDA-231-CLUi cells versus native MDA-231 cells and MDA-231-Vec controls. The TIMP-1 mRNA levels were unaffected by silencing the CLU gene (Fig. 2B) .
Silencing of the CLU gene in MDA-231 cells was associated with a decrease in ERK and p-ERK protein levels compared with controls ( Fig. 3A) . Reintroduction and re-expression of the CLU gene in MDA-231-CLUi cells restored ERK, p-ERK and MMP-9 protein levels to those of controls ( Fig. 3B) . Analysis by RT-PCR showed that MMP-9 mRNA levels were similarly restored (Fig. 3C) . Treatment of MDA-231-CLUi cells with the mitogen-activated kinase (MEK) inhibitor PD98059 (50 µM) eliminated the effect of reintroducing the CLU gene on MMP-9 mRNA and protein levels (Fig. 3B, 3C ).
Levels of cell migration and invasion that were similar to those seen in native MDA-231 cells or MDA-231-Vec control cells occurred following reintroduction and expression of the CLU gene in MDA-231-CLUi cells. Treatment of these MDA-231-CLUi cells with the mitogen-activated protein kinase (MEK) inhibitor PD98059 significantly reduced these effects (P < 0.01; Figs 4A, 4B) .
The C57BL/6 mice were injected with MDA-231, MDA-231-Vec, or MDA-231-CLUi cells via the tail veins and examined 4 weeks later for metastatic nodules of the lung. The majority of C57BL/6 mice injected with 
Discussion
The present study showed that the CLU gene could be successfully silenced by specific small-interfering RNA-induced degradation in a human breast cancer cell line, and that secreted CLU protein is essential for cell The reintroduction and re-expression of the CLU gene in MDA-231-CLUi cells restored the invasive phenotype, suggesting that the primary function of CLU in MDA-231 cells is proinvasive and may regulate the aggressiveness of breast cancer cells. The present study also provided mechanistic insights into how CLU may regulate the invasive phenotype in MDA-231 cells.
The most well-known of the ECMdegrading enzymes are the MMPs, which are a family of at least 20 structurally and functionally homologous proteins that are capable of degrading all components of the ECM. A positive correlation has been reported between MMP-9 and tumour metastasis in several types of epithelial cancer, 23, 24 suggesting an important functional role for these proteinases in metastasis. Metastasis of cancer cells requires several sequential steps including changes in cell-ECM interactions, dissociation of intercellular adhesion complexes, separation 25 The mechanisms of MMP9 gene activation in human cancer cells are not well defined. The present study demonstrated that silencing of the CLU gene reduced migration and invasion in MDA-231 cells and decreased MMP9 expression, and that the reintroduction and re-expression of the CLU gene in MDA-231-CLUi cells restored the invasive phenotype and increased MMP9 expression, indicating that CLU is a potent promoter of the MMP9 gene. In contrast, TIMP1 expression was unaffected by the silencing of the CLU gene, suggesting that the effects of CLU are not mediated through the regulation of this gene.
The ERK1/2 cascade is a key signalling pathway that regulates a wide variety of cellular processes, predominantly related to proliferation, differentiation and survival, but also including apoptosis and stress responses. 26 ERK1/2 is also a major regulator of MMP-9 activity. 16 -19 The present study showed that production of activated ERK (i.e. p-ERK) and MMP-9 was CLU-dependent as both proteins were reduced in MDA-231-CLUi cells. The MEK inhibitor PD98059 blocked any increase in p-ERK and MMP-9, and the migration/invasion ability of the MDA-231-CLUi cells into which the CLU gene had been reintroduced.
Taken together, these data suggest that expression of the CLU gene activates the ERK cascade and upregulates MMP-9, contributing to the invasive phenotype of human breast cancer cells. Considering the overwhelming evidence for a role for MMP-9 in tumour cell invasion, inhibitors of MMP-9 may have a role in the prevention of breast cancer. In addition, silencing of the CLU gene may be of benefit in reducing the invasiveness of breast cancer.
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